Green Cross Holdings

Green Cross Holdings has a debt-to-equity ratio of 1.49, indicating a relatively high level of leverage in its capital structure. The company's liquidity position is assessed as medium, with a current ratio of 0.96, suggesting that it has nearly equal current liabilities to current assets. The company's cash and equivalents amount to KRW 20.56 billion, which is significantly lower than its long-term debt of KRW 139.03 billion, resulting in a negative net cash position.

In terms of profitability, Green Cross Holdings reported a net loss of KRW 40.77 billion in the latest period, with an operating loss of KRW 30.99 billion. The company's return on equity (ROE) is -4.37%, and its return on assets (ROA) is -1.09%, both of which are below the industry median for pharmaceutical companies. These metrics indicate that the company is currently unprofitable and underperforming relative to its peers.

The company's revenue is primarily concentrated in its domestic market, with South Korea accounting for the majority of its sales. Green Cross Holdings operates in a highly competitive pharmaceutical industry, where revenue concentration can pose a risk if market conditions in South Korea deteriorate. The company does not disclose significant international revenue, which limits its geographic diversification.

Looking ahead, Green Cross Holdings is expected to face continued financial pressure, with a negative operating cash flow of KRW 90.73 billion and a free cash flow of KRW -52.49 billion. The company's capital expenditures amounted to KRW 15.61 billion, reflecting ongoing investment in its operations. However, the lack of positive cash flow from operations may constrain its ability to fund future growth without external financing.

The company's risk profile is elevated due to its high leverage and negative net cash position. The risk assessment indicates a medium liquidity risk, with the company's cash and equivalents insufficient to cover its long-term debt obligations. While the dilution risk is currently assessed as low, the company's financial position may necessitate additional equity or debt financing in the future, which could lead to share dilution.

Recent filings and transcripts indicate that Green Cross Holdings is actively managing its financial challenges, with a focus on cost control and operational efficiency. The company has also been investing in research and development to expand its product portfolio and improve long-term competitiveness. However, the ongoing financial losses and liquidity constraints remain key concerns for investors.

Green Cross Holdings (005250.KS), operating under the display name Gc Corp, has been formally classified within the Healthcare economic sector with a specific focus on Pharmaceuticals. This taxonomic update provides a clearer structural definition of the company’s primary business activities, establishing a baseline for sector-specific analysis. The risk profile for the entity has also been updated with new assessments. Dilution risk is now categorized as low, indicating a stable capital structure regarding share count expansion. Conversely, liquidity risk has been assessed at a medium level, suggesting moderate constraints or variability in the company’s ability to meet short-term obligations. These changes represent the first tracked-field updates for the company, with the maximum severity of the changes rated as medium. The introduction of these specific risk and classification metrics fills previous data gaps, allowing for a more granular evaluation of the firm’s operational and financial standing. Currently, the company shows no recorded analyst coverage, index memberships, or identified top holders in the available data. The absence of these external validation metrics means the newly established risk and sector classifications serve as the primary framework for understanding Gc Corp’s current market position. [doc:005250.ks-ha-financials]

Revenue grew 11.2% year-over-year to 2.45 trillion KRW, demonstrating top-line expansion despite profitability challenges.

Cash conversion ratio of 2.23 exceeds the 75th percentile of the pharmaceutical cohort, indicating superior cash generation efficiency.

Capital expenditure relative to revenue is above the cohort median, suggesting continued investment in future growth drivers.

Gross profit remains substantial at 682.7 billion KRW, providing a buffer for potential operating leverage improvements.

Dilution risk is assessed as low, protecting existing shareholders from immediate equity value erosion.

Debt-to-equity ratio of 1.49 sits in the bottom quartile of peers, indicating excessive financial leverage and risk.

High credit risk flags combined with negative ROE of -4.4% suggest fundamental financial distress.